Early success in national $7 million competition highlights how human-cell models could speed up testing for brain therapies.
Longevity research has made some remarkable strides in understanding what happens to the aging body. Scientists can increasingly target senescent cells, tweak metabolism, reprogram cells and explore regenerative therapies with growing confidence. But when those same ideas are aimed at the brain, progress slows dramatically.
The reason is simple. The brain is protected by one of the body’s most formidable security systems: the blood-brain barrier. Think of it as an elite border control that decides what enters the brain and what stays out. It is extraordinarily good at keeping harmful substances away. Unfortunately, it is just as good at blocking medicines. Around 98% of small-molecule drugs – and nearly all biologic therapies – never make it through.
That raises a question with profound implications for longevity: if researchers can finally understand, predict and safely navigate this barrier using artificial intelligence, could brain-focused longevity therapies finally begin catching up with the rapid advances being made elsewhere in aging science?
It also presents another challenge. Today, researchers often spend years waiting for diseases such as Alzheimer’s or Parkinson’s to develop before they can evaluate whether a therapy works. But what if they could recreate an aging human blood-brain barrier in the laboratory instead? Could preventative therapies be developed years earlier, before irreversible damage has already begun?
Those questions are at the core of a new announcement from California-based Frontier Bio – one that, while technical on the surface, reflects a much larger shift in how medicine itself is evolving.
Frontier Bio has been named a Phase 1 winner of the Complement-ARIE New Approach Methodologies (NAMs) Reduction to Practice Challenge, a national competition led by the NIH Common Fund in collaboration with the FDA and Environmental Protection Agency, and administered through the NASA Tournament Lab [1]. The award advances Frontier Bio to the next stages of the multi-year competition, which carries a total prize pool of $7 million, and provides a cash award for the company’s early success.
Teaching AI to understand the brain’s gatekeeper
Imagine trying to test a new bridge without ever sending real traffic across it. You could build a highly realistic model, observe how vehicles behave and spot weaknesses before anyone drives over the real thing. Frontier Bio is applying a similar philosophy to the blood-brain barrier.
The company grows living human cells into a miniature laboratory model that recreates the barrier separating the bloodstream from the brain. Artificial intelligence then studies ordinary microscope images to determine what happens when potential therapies encounter that barrier.
Does the drug successfully cross? Does it weaken the barrier? Or does it leave everything unchanged? Instead of relying on expensive specialized equipment or lengthy animal studies, the AI extracts measurable insights from standard microscope images, allowing researchers to evaluate therapies more quickly and at lower cost. The goal is not simply to produce more data. It is to generate data that better reflects what may actually happen in people.
“Predicting how the human brain responds to a therapeutic is one of the most expensive unsolved problems in drug development, and animal models consistently fail to bridge that gap,” said Eric Bennett, CEO of Frontier Bio. “We are building NeuroTraX-AI into the scalable, human-based alternative developers need, right as regulators are calling for one.”
A regulatory shift years in the making
The FDA’s 2025 roadmap, enabled through the FDA Modernization Act 2.0, outlines a future in which animal testing is gradually supplemented (and, in some cases, replaced) by human-based laboratory models and advanced computational methods. This represents more than a scientific upgrade. It reflects an acknowledgment that human biology is extraordinarily difficult to imitate, and that treatments performing well in animals often behave very differently in people. While Frontier Bio is far from the only company seeking to capitalize on this regulatory shift, its platform reflects the broader industry push toward human-first testing
Brain disorders make that mismatch even more apparent. Developing a therapy for neurological disease typically costs billions of dollars and can take well over a decade. Yet fewer than one in ten central nervous system drug candidates entering clinical trials ever reaches patients. That is not necessarily because the ideas are wrong. Often, researchers simply lack a reliable way of predicting how the human brain will respond until very late in development.
Much of today’s excitement focuses on extending healthspan across the body, but healthy aging without brain health is only part of the equation. The next generation of longevity therapies is increasingly expected to target cognitive decline, neuroinflammation and age-related neurological disease before symptoms appear. Achieving that future requires better ways to study the brain safely, accurately and much earlier than current methods allow.
Frontier Bio is now expanding NeuroTraX-AI’s training library, increasing its testing capacity, working towards validation and pursuing partnerships with drug and cell therapy developers as it moves toward commercial deployment.
Whether the platform ultimately becomes an industry standard remains to be seen. But its NIH recognition reflects something larger than one company’s progress. It signals that the future of drug development may depend less on observing disease after it happens and more on faithfully recreating human biology before it does.
If the blood-brain barrier has long been the gate slowing progress against neurodegenerative disease, technologies like NeuroTraX-AI suggest that the key may finally be taking shape. And if longevity is ultimately about preserving not only years of life but years of healthy cognition, unlocking that gate may prove just as transformative as any breakthrough aimed at slowing aging itself.
